Hemab Therapeutics Holdings, Inc. Common Stock

Hemab Therapeutics Holdings, Inc. Common Stock

COAG

Get informed when a big investor buys or sells

+ Follow
Market Cap$1.48B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Hemab Therapeutics Holdings, Inc. Common StockHemab Therapeutics Holdings, Inc. Common Stock-24.1----
$3.16

Current Fair Value

90.3% downside

Overvalued by 90.3% based on the discounted cash flow analysis.

Share Statistics

Market cap$1.48 Billion
Enterprise Value$1.24 Billion
Dividend Yield$- (-)
Earnings per Share$-2.33
Beta1.85
Outstanding Shares30,111,000

Return

Return on EquityNaN%ROE
Return on AssetsNaN%
Return on Invested CapitalNaN%

Valuation & Multiples

P/E Ratio-24.14P/E Ratio
PEG-PEG
Price to Sales-Price to Sales
Price to Book Ratio2.17Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-
Enterprise Value to Net Income-
Total Debt to Enterprise0
Debt to Equity0Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 20, 2026
EPS Estimate
$-0.73
Average shareholder expectation
Revenue Estimate
-
Average shareholder expectation

Next Earnings Call

Expected Date
November 10, 2026
EPS Estimate
$-0.50
Average shareholder expectation
Revenue Estimate
-
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %120.78%▲ 120.78%
Total Invested$1.34B
Investors Holding57▲ 57.00%

ESG Score

No data

About Hemab Therapeutics Holdings, Inc. Common Stock

72 employees
CEO: Benny Sorensen

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology firm dedicated to transforming the treatment of blood coagulation disorders. Operating in the United States and Denmark, its mission is to enhance life and resilience fo...